Publication

WFH •
20 April, 2026 •
•

Joint Health Outcomes with Efanesoctocog Alfa in Adults/Adolescents from XTEND-1 Continuing in XTEND-ed: Plain Language Summary

Christoph Königs, Annette von Drygalski, Cedric Hermans, Barbara A. Konkle, Paul Van der Valk, Liane Khoo, Nobuaki Suzuki, Liqi Feng, Umer Khan, Linda Bystrická, Jennifer Dumont, Elena Santagostino, Lara Mamikonian, Robert Klamroth

Publication

WFH •
20 April, 2026 •
•

Hemophilia Life Stages and Changes Global Survey of People with Hemophilia, Caregivers, and Hematologists: Patient Experience According to Disease Severity and Gender

Mark W. Skinner, Kim Isenberg, Maria Elisa Mancuso, Stacy E. Croteau, Jacose Bell, Pamela Wilton, Michael Recht, Lynn Malec

Available materials

Poster

Publication

WFH •
20 April, 2026 •
•

Plain Language Summary: What is Extravascular Distribution of Factor IX and how does it Affect Management of Those with Haemophilia B?

Cedric Hermans, Carmen Escuriola Ettingshausen, Michael Laffan, Davide Matino, Niamh O’Connell, Robert Sidonio, Rolf Ljung

Available materials

Poster

Publication

EAHAD •
6 February, 2026 •
•

Efanesoctocog Alfa Prophylaxis for People with Severe Haemophilia A: Third Interim Results from the XTEND-ed Long-Term Extension Study

Physical Activity and Bleed Prevention for People With Severe Haemophilia A Treated With Once-Weekly Efanesoctocog Alfa: A Plain-Language Summary of 12-Month Interim Results From the FREEDOM Study

Joint Health Outcomes with Efanesoctocog Alfa in Adults/Adolescents from XTEND-1 Continuing in XTEND-ed: Plain Language Summary

Hemophilia Life Stages and Changes Global Survey of People with Hemophilia, Caregivers, and Hematologists: Patient Experience According to Disease Severity and Gender

Plain Language Summary: What is Extravascular Distribution of Factor IX and how does it Affect Management of Those with Haemophilia B?

Efanesoctocog Alfa Prophylaxis for People with Severe Haemophilia A: Third Interim Results from the XTEND-ed Long-Term Extension Study

Clinical, Psychosocial, Quality of Life Outcomes and Patient-Physician Discrepancies in Joint Damage Reporting in a cohort of People with Haemophilia A: real-world insights from the CHESS III Study

Treatment of Bleeding Episodes with Efanesoctocog Alfa in Adults, Adolescents, and Children with Severe Haemophilia A: Third Interim Analysis of the XTEND-ed Long-term Extension Study

Long-Term Clinical Outcomes of Efanesoctocog Alfa in Patients with Severe Haemophilia A: European Results from the Third Interim Analysis of XTEND-ed